TIDMHIK 
 
 
Hikma Pharmaceuticals Plc 
17 July 2009 
 
 
 HIKMA PHARMACEUTICALS PLC 
 
 
Hikma signs licensing agreement with Faes 
Farma SA for anti-histamine Bilastine 
 
London, 16 July 2009: Hikma Pharmaceuticals PLC ("Hikma") 
(LSE:HIK) (NASDAQ Dubai: HIK), a leading speciality pharmaceutical company, 
today announces that its subsidiary Hikma Pharmaceuticals LLC has signed a 
licensing agreement for the anti-histamine Bilastine with FAES FARMA, S. A., a 
Spanish pharmaceutical company, for the Middle East & North Africa ("MENA") 
region. 
 
Through this agreement FAES FARMA grants exclusive rights for the manufacture 
and distribution of Bilastine to Hikma for 17 MENA countries, while reserving 
its co-marketing rights in some of them. 
 
Bilastine is a highly selective oral anti-histamine with an excellent safety 
profile aimed to treat allergic rhinitis and chronic urticaria. The 
anti-histamine market in the MENA region is approximately $115 million and has 
been growing at a rate of approximately 13% (Source: IMS Health). 
 
Hikma will leverage its position as the largest regional pharmaceutical 
manufacturer and marketer in the MENA region with its extensive sales force of 
more than 1,100 sales representatives to drive sales of this important product. 
Hikma expects to achieve annual Bilastine sales of over $10 million after 
launching the product throughout its whole MENA territory. 
 
It is expected that this agreement will be followed by others between HIKMA and 
FAES for additional licensed products. 
 
Said Darwazah, Hikma's Chief Executive Officer commented: "This agreement 
reinforces our position as the partner of choice for marketing branded products 
in the MENA region. In-licensing is a key part of our growth strategy in the 
region and accounts for more than 30% of sales in our Branded business. We are 
pleased to have secured the license for this important anti-histamine and look 
forward to making Bilastine available to our customers across the MENA region." 
 
=- ENDS - 
 
Enquiries 
 
Hikma Pharmaceuticals PLC 
Susan Ringdal, Investor Relations Director Tel: +44 (0)20 7399 2760 
 
Brunswick Group 
Jon Coles / Justine McIlroyTel: +44 (0)20 7404 5959 
 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products. Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe. In 2008, Hikma achieved revenues of 
$581 million and profit attributable to shareholders of $57 million. For news 
and other information, please visit www.hikma.com. 
 
About the MENA region 
The MENA region has a population of 270 million people and comprises the 
following countries: Morocco, Algeria, Tunis, Libya, Egypt, Sudan, Jordan, 
Lebanon, Syria, Iraq, Kuwait, Bahrain, Qatar, United Arab Emirates, Saudi 
Arabia, Yemen and Oman. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAUNVORKBRBAAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.